Valuation: BLS Pharmaceuticals Limited

Market Cap 235M 163M 145M 135M 123M 233M 15.7B 1.64B 635M 8.02B 613M 600M 25.75B P/E 2025
17.8x
P/E 2026 13.9x
Enterprise Value 230M 160M 142M 133M 121M 228M 15.37B 1.6B 622M 7.86B 600M 587M 25.22B EV / Sales 2025
2.82x
EV / Sales 2026 2.82x
Free-Float
41.59%
Yield 2025 *
-
Yield 2026 -
1 week-0.97%
Current month-2.86%
1 month-7.69%
3 months+9.68%
6 months+59.38%
Current year+142.86%
1 week 0.94
Extreme 0.945
1.12
1 month 0.94
Extreme 0.945
1.3
Current year 0.36
Extreme 0.36
1.3
1 year 0.33
Extreme 0.33
1.3
3 years 0.04
Extreme 0.04
1.3
5 years 0.04
Extreme 0.04
1.3
10 years 0.04
Extreme 0.04
1.4
Manager TitleAgeSince
Chief Executive Officer - 19/05/2023
Director of Finance/CFO 72 01/09/2016
Chief Operating Officer - -
Director TitleAgeSince
Chairman 67 05/12/2012
Director/Board Member 72 30/06/2022
Director/Board Member - 19/05/2023
Date Insider Type Main position Quantity % Market Cap. Importance
14/5/26 Buy 5,000,000 0.2202%
14/5/26 Exercice 5,000,000 0.2202%
22/3/26 Buy

Chief Executive Officer

1,800,000 0.0804%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-0.97%+148.78%+827.27% 163M
+4.16%+3.04%+49.37%+94.17% 74.16B
-3.11%-3.53%+21.92%+74.60% 57.39B
+0.89%-0.63%+4.28%+34.51% 47.64B
+0.36%+0.81%+352.17%+689.61% 44.29B
-0.96%-4.50%+26.36%+33.18% 42.5B
-0.20%-0.77%+3.74%+100.60% 40.71B
-0.54%+2.93%+9.31%+50.41% 30.97B
-2.68%+2.92%+29.63%+19.50% 28.53B
+0.05%-1.64%-7.28%-14.06% 24.34B
Average -0.20%-0.63%+63.83%+190.98% 39.07B
Weighted average by Cap. +0.12%-0.84%+58.80%+130.20%

Financials

2025 2026
Net sales 29.28M 20.35M 18.08M 16.88M 15.38M 29.01M 1.96B 204M 79.14M 1B 76.41M 74.75M 3.21B 73.91M 51.37M 45.64M 42.6M 38.83M 73.23M 4.94B 516M 200M 2.52B 193M 189M 8.1B
Net income 4.9M 3.41M 3.03M 2.82M 2.57M 4.86M 327M 34.19M 13.25M 167M 12.79M 12.51M 537M 15.4M 10.7M 9.51M 8.87M 8.09M 15.25M 1.03B 107M 41.61M 526M 40.18M 39.31M 1.69B
Net Debt -6.13M -4.26M -3.79M -3.54M -3.22M -6.08M -410M -42.79M -16.58M -210M -16.01M -15.66M -672M -4.86M -3.37M -3M -2.8M -2.55M -4.81M -324M -33.87M -13.12M -166M -12.67M -12.4M -532M
Logo BLS Pharmaceuticals Limited
BLS Pharmaceuticals Limited, formerly Bioxyne Limited, is an Australia-based international consumer health and pharmaceutical company. The Company is focused on health and wellness products, psychotropic and investigational medicines. The Company operates through three segments: Wholesale PCC/USA, Consumer Health Products UK/ EU/JPN, and Pharmaceuticals AUS. Its subsidiary, Breathe Life Sciences (BLS) manufactures, commercializes, and distributes plant-based wellness products and supplements, including cannabidiol (CBD), cannabis extracts, vitamins, manuka honey, skin care products and mushroom complexes. BLS operates in Australia, the United Kingdom, Japan, and Europe with four accredited manufacturing facilities across four countries: Japan, Australia, the United Kingdom, and Czechia. The Company directs the sales arm and has developed a range of functional food products containing ingredients sourced exclusively from New Zealand and sold in Asia.
Employees
-
Date Price Change Volume
02/10/26 A$1.020 0.00% 33,148
01/10/26 A$1.020 -2.86% 238,588
30/09/26 A$1.050 +5.53% 210,245
29/09/26 A$0.9950 -1.97% 584,377
28/09/26 A$1.015 -1.46% 817,109

Annual profits - Rate of surprise